Xvivo announces that the company’s patent for the heart preservation fluid has been approved in the US and Europe. We believe that the patent, together with the already approved patents for the heart evaluation equipment (Europe, Australia, Canada and China) will give the company a strong IP protection. Today’s news was, however, in line with our expectations and does not impact our valuation